World Health Organization classification of tumours of the breast 6th edition 2026

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort

Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study

Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial

Clinical Performance of Contrast-Enhanced Mammography Versus Breast MRI in Women at Increased Breast Cancer Risk

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Second Ipsilateral Breast Cancer Event: True Recurrence, New Primary, or True Recurrence Like?

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy